Retrospective cohort studies and real-world analyses reported GLP-1 RA use has been associated with lower rates of IBD-related hospitalizations, surgeries, and corticosteroid prescriptions in patients with type 2 diabetes or obesity (13–15). This evidence concerns the gene GLP1R and inflammatory bowel disease.